资料显示，华仁药业股份有限公司位于山东省青岛市高科技工业园株洲路187号，成立日期1998年5月20 日，上市日期2010年8月25日，公司主营业务涉及大输液(包括非PVC软袋、直立式软袋、塑瓶、玻瓶大 输液)、腹膜透析液、呼吸科用药、精麻科用药以及原料药、配套医药包材、医疗器械、大健康产品。 主营业务收入构成为：基础输液40.63%，腹透液34.90%，治疗制剂14.92%，医疗器械8.14%，其他 1.41%。 截至11月10日，华仁药业股东户数4.01万，较上期减少1.23%；人均流通股29447股，较上期增加 1.25%。2025年1月-9月，华仁药业实现营业收入9.76亿元，同比减少9.07%；归母净利润5457.98万元， 同比减少42.87%。 11月17日，华仁药业涨0.00%，成交额7944.32万元。两融数据显示，当日华仁药业获融资买入额408.32 万元，融资偿还637.98万元，融资净买入-229.66万元。截至11月17日，华仁药业融资融券余额合计2.34 亿元。 融资方面，华仁药业当日融资买入408.32万元。当前融资余额2.34亿元，占流通市值的5.46%，融资余 额低于近一年5 ...

Group 1 - On September 24, Huaren Pharmaceutical's stock rose by 1.88%, with a trading volume of 58.77 million yuan [1] - The financing data on the same day showed a financing purchase amount of 7.48 million yuan, a repayment of 6.17 million yuan, resulting in a net financing purchase of 1.31 million yuan [1] - As of September 24, the total balance of margin trading for Huaren Pharmaceutical was 261 million yuan, accounting for 6.79% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 20, the number of shareholders for Huaren Pharmaceutical was 40,500, a decrease of 1.46% from the previous period [2] - The average circulating shares per person increased by 1.48% to 29,156 shares [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 3 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends [3] - In the last three years, the cumulative dividend payout amounted to 49.65 million yuan [3]